Post by icemandios on May 5, 2022 12:52:44 GMT
Phio Pharmaceuticals Announces Senior Leadership Personnel Change
PR Newswire
MARLBOROUGH, Mass. , May 5, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, announced today the departure of Dr. Gerrit Dispersyn from his role as President and Chief Executive Officer. Dr. Dispersyn joined Phio in 2017 as Chief Development Officer and was subsequently appointed President and CEO in March 2019 . During his tenure as CEO Gerrit continued Phio's transition to become an immuno-oncology based enterprise originally initiated by Dr. Geert Cauwenbergh . This refocus centered on Phio's INTASYL therapeutic platform, recently approved for initial human clinical use in addressing cutaneous melanoma. Dr. Geert Cauwenbergh , former President and CEO, will take on the responsibility of Principle Executive Officer reporting to the Phio Board of Directors chaired by Robert Bitterman until such time as a satisfactory executive search has completed.
Logo - mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor microenvironment. The Company's goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com .
PR Newswire
MARLBOROUGH, Mass. , May 5, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, announced today the departure of Dr. Gerrit Dispersyn from his role as President and Chief Executive Officer. Dr. Dispersyn joined Phio in 2017 as Chief Development Officer and was subsequently appointed President and CEO in March 2019 . During his tenure as CEO Gerrit continued Phio's transition to become an immuno-oncology based enterprise originally initiated by Dr. Geert Cauwenbergh . This refocus centered on Phio's INTASYL therapeutic platform, recently approved for initial human clinical use in addressing cutaneous melanoma. Dr. Geert Cauwenbergh , former President and CEO, will take on the responsibility of Principle Executive Officer reporting to the Phio Board of Directors chaired by Robert Bitterman until such time as a satisfactory executive search has completed.
Logo - mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor microenvironment. The Company's goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com .